Peer Review History

Original SubmissionJuly 8, 2023
Decision Letter - Azmeraw Ambachew Kebede, Editor

PONE-D-23-00901Measuring the Effects of a Nurse-led Intervention on Frailty Status of Older People Living in the Community in Ethiopia: A Protocol for a Quasi-experimental StudyPLOS ONE

Dear Dr. Kasa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please submit your revised manuscript by Sep 18 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Azmeraw Ambachew Kebede, MSc

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include the following request for minor text overlap and do not ping with follow up:

"We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

- https://doi.org/10.3390/ijerph17186660

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed."

3. Please include the following request in the decision letter, and ping me with follow up." Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

4. Please ask the authors to include an explanation for the retrospective CT registration and confirmation that all related CTs are registered, using send back in ITC desk notes. At RTC, please check the authors' response and ping me if the authors do not address this.

5. Thank you for stating the following financial disclosure:

"The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

7. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: You have clearly identified the rationale for the study. Developing an education package and delivering it is an ambitious project. I wish you well with this.

As a new program, I would think determining its acceptability and identifying any areas for modification are important outcomes. Yet I see no mention of acceptability/ adherence measures as outcomes.

How will the program’s acceptability with those delivering it and those reviewing it be assessed? Will you seek feedback on the training book? Will you measure adherence? If so, how? Meeting with the CHWs each month would be one measure. How do you determine compliance with the recommendations for exercise or diet? Or is this not possible?

Methods: Line 103

Please include the name of the instruments used to measure the primary outcome (frailty status) and the instruments used for the secondary measures. Table 3 lists and outlines the outcome measures (i.e. the score range, number of questions and a reference for the instrument). Maybe refer to this table earlier in the text in the methods, rather than later (in the data collection), or move text from this table into the methods section.

EDITS:

Line 123: as your sample calculation was an a priori analysis, change from future tense to past tense, i.e. sample size WILL be calculated, to sample size WAS calculated ….

Line 154 – change singular to plural, i.e. study participant’s to study participants’ involvement.

Reviewer #2: This single group study aims to design, implement, and evaluate a nurse-led intervention to reduce frailty among older people in Ethiopia. Data will be repeatedly collected, at baseline, immediately after intervention, and 12 weeks post-intervention. Data will be collected on frailty, nutrition status, activities of daily living, depression and quality of life.

Minor revisions:

1- Abstract: Grammatical error: Statistical

2- Line 126: Indicate the statistical testing method which achieves 95% power.

3- Line 220: Categorical data is typically summarized using both frequencies and percentages.

4- Line 220: State the statistical approach that will be used to test for normality of the data.

5- Since data will be collected at 3 time points, specifically indicate which outcomes and time points will be compared using Fisher’s exact tests, paired sample t-tests, and GLM with repeated measures ANVOVAs.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor, we would like to thank you for the time to review our manuscript and for sharing supporting reference materials. In the current version of the manuscript, we included a figure that reflects the construct of the intervention. All the amendments and revisions made are highlighted in light yellow colour.

Academic editor’s comment: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Author’s response/explanation: Thank you for sharing the link to access the templates. We assure you that the manuscript meets PLOS ONE’S style requirements, including file naming. In the revised manuscript a figure has been included (see p. 7, line 170).

Academic editor’s comment: Please include the following request for minor text overlap and do not ping with follow up: "We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:- https://doi.org/10.3390/ijerph17186660. In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed."

Author’s response/explanation: For the requested minor textual overlaps, we ensured all the sources were cited.

We thought that we acknowledged the sources of information with appropriate citations. For example, information taken from the previously mentioned source/publication was cited as indicated using reference number 24. In the meantime, if still there are some concerns, we kindly wait for your advice.

Academic editor’s comment: 3. Please include the following request in the decision letter, and ping me with follow up." Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

Author’s response/explanation: The requested PLOS’ questionnaire on inclusivity in global research was completed and uploaded as ‘Supporting Information’.

Academic editor’s comment: Please ask the authors to include an explanation for the retrospective CT registration and confirmation that all related CTs are registered, using send back in ITC desk notes. At RTC, please check the authors' response and ping me if the authors do not address this.

Author’s response/explanation: Update made to detail about clinical trial registration to ensure clarity about when the clinical trial was registered (see p.5, lines 115-119).

Academic editor’s comment: Thank you for stating the following financial disclosure: "The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Author’s response/explanation: Regarding the financial disclosure, we want to assure you the following:

a. The source of funding for this study has been stated in the ‘funding statement’ section (see p.12, lines 284 to 287)

b. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

c. Not applicable.

d. The authors received no specific funding for this work except the student received a support Scholarship in the form of the University Postgraduate Award (UPA).

Amendments are included in the cover letter and indicated.

Academic editor’s comment: 6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Author’s response/explanation: The manuscript was edited to more clearly describe the minimal data set underlying the results described in the ‘Data Availability Statement’ (see p. 13, lines 304-305).

Academic editor’s comment: We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Author’s response/explanation: We thought that this had been done mistakenly during the submission process. We would like to publish our manuscript without holding for the provision of accession or DOI. Because we do not have any repository data at the acceptance. Information concerning this has been updated in the ‘Data Availability Statement’ section.

Reviewer 1 comment: You have clearly identified the rationale for the study. Developing an education package and delivering it is an ambitious project. I wish you well with this.

Author’s response/explanation: Thank you so much for your positive comments.

Reviewer 1 comment: As a new program, I would think determining its acceptability and identifying any areas for modification are important outcomes. Yet I see no mention of acceptability/ adherence measures as outcomes.

Author’s response/explanation: The manuscript was amended with additional detail addressing this comment in the ‘Strengths and limitations’ section (see p. 9, line 228-231).

Reviewer 1 comment: How will the program’s acceptability with those delivering it and those reviewing it be assessed?

Author’s response/explanation: The comments addressed in the revised manuscript (see p. 9, lines 228-232).

Reviewer 1 comment: Will you measure adherence? If so, how? Meeting with the CHWs each month would be one measure.

Author’s response/explanation: The data collectors record completion of each of the six sessions by each of the participants. This will enable reporting on adherence to the intervention (see 9. 226-228).

Reviewer 1 comment: Will you seek feedback on the training book?

Author’s response/explanation: Feedback from the participants was taken into consideration. Moreover, during the intervention period, there will be a fortnightly 5 to 10-minute follow-up phone call with participants to receive feedback about the education sessions and provide opportunistic counselling on the specific topics (see p. 10, line 231-232).

Reviewer 1 comment: How do you determine compliance with the recommendations for exercise or diet? Or is this not possible?

Author’s response/explanation: The comment is addressed in the revised manuscript under the ‘strengths and limitations’ subheading (see p. 12, lines 278-282).

Reviewer 1 comment: Please include the name of the instruments used to measure the primary outcome (frailty status) and the instruments used for the secondary measures. Table 3 lists and outlines the outcome measures (i.e. the score range, number of questions and a reference for the instrument). Maybe refer to this table earlier in the text in the methods, rather than later (in the data collection), or move text from this table into the methods section.

Author’s response/explanation: The names of the instruments used to measure the primary outcome (frailty status) has been included in the revised manuscript (see p.5, line 105). The names of the instruments used to measure the secondary outcomes are also included in the revised manuscript (see p. 5, lines 108 to 112)

We agree with the comments to refer to Table 3 earlier. To make the tables in their order, Table 3 in the previous manuscript has now been amended as Table 2 in the revised manuscript (see p. 5, line 112).

Reviewer 1 comment: Line 123: as your sample calculation was an a priori analysis, change from future tense to past tense, i.e. sample size WILL be calculated, to sample size WAS calculated

Author’s response/explanation:Amendment made to sample size calculation (see p.6, line 131).

Reviewer 1 comment: Line 154 – change singular to plural, i.e. study participant’s to study participants’ involvement.

Author’s response/explanation: On the ‘Authors access to study participant information and confidentiality’ amendments from study participant’s to study participants’ (see p. 7, line 163.

Reviewer 2 comment: Abstract: Grammatical error: Statistical

Author’s response/explanation: We could not find the typo for ‘statistical’. Please provide further detail so we can address this revision.

Reviewer 2 comment: Line 126: Indicate the statistical testing method which achieves 95% power.

Author’s response/explanation: Regarding the statistical testing achieving 95%, a revision made (see p. 6, lines 133 to 134).

Reviewer 2 comment: Line 220: Categorical data is typically summarized using both frequencies and percentages.

Author’s response/explanation: Regarding categorical data, a revision made (see p 10, line 238).

Reviewer 2 comment: Line 220: State the statistical approach that will be used to test for normality of the data.

Author’s response/explanation: Regarding the statistical approach to test the normality of the data revision made (see p. 10 line 239).

Reviewer 2 comment: Since data will be collected at 3 time points, specifically indicate which outcomes and time points will be compared using Fisher’s exact tests, paired sample t-tests, and GLM with repeated measures ANVOVAs.

Author’s response/explanation: Regarding both the primary and secondary outcomes measured at three points in times, revisions made. (see p. 10, lines 240-242).

Thank you!

Attachments
Attachment
Submitted filename: Response to Reviewers_PLOS ONE_05.10.23.docx
Decision Letter - Azmeraw Ambachew Kebede, Editor

PONE-D-23-00901R1Measuring the Effects of a Nurse-led Intervention on Frailty Status of Older People Living in the Community in Ethiopia: A Protocol for a Quasi-experimental StudyPLOS ONE

Dear Dr. Kasa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Azmeraw Ambachew Kebede, MSc

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #3: Yes

Reviewer #4: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #3: Yes

Reviewer #4: No

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The authors have responded well to comments of the reviewers. The manuscript is interesting and well-written.

Regarding reviewer 1, a simple measure of compliance could be the percentage of participants completing all 6 sessions as a secondary endpoint.

Minor comments:

1. Abstract: please specify the expected number of participants

2. Methods: I recommendend to add the number of falls among the secondary outcomes "number of falls in the 3 months prior to intervention, number of falls at 3 months, 6 months and 12 months").

3. Methods: non-inclusion criteria, replace "cognitive impairment" by "major cognitive impairment"

4. Methods: Student's t-test will be probably used to compare the level of frailty with categorical variables (sex, education etc). Add Student's t-test.

I recommend this manuscript for publication.

Best regards

Boucaud-Maitre Denis

Reviewer #4: 1.Line 111.6, it is unclear why the study was registered PROSPECTIVELY 3 months after data collection. Should it be RETROSPECTIVELY as registration of the study happened after the start of data collection?

2.Line 113-133, If the data is assumed to be normally distributed, why paired-t test is not used for sample size calculation? Also, please clarify the end point of the primary outcome for sample size calculation, either from T0 to T1 or T0 to T2. The author should state clearly which outcome measure is used for sample size calculation as the assumed effect size of 0.5 means it is assumed that the effect size of the intervention on the primary outcome of the study is 0.5, which should also be supported by evidence.

3.Line 137-144, it is unclear how the subjects will be recruited, either from the poster or CHW proactively to recruit subjects through the available list. More specifically, which sampling method will be used? The section Recruitment should place after the section on Eligibility.

4.Line 169, for the NLI program, the sessions can be distinct and interconnected (independent means they are unconnected)

5.Line 226. Some descriptions of the outcome measures should be provided in the text, rather than provided in the hypothesis under Study design and hypothesis. Moreover, some of the outcomes were not touched such as recent appetite. Acceptability of the program should also be measured from the perspectives of the participants on top of the interventionist (i.e., CHWs)

6.Line 272-285, Please group the points for two subsections of strengths and limitations of the study.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Boucaud-Maitre Denis

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Reviewer 3 Comments: Abstract: please specify the expected number of participants

Authors' explanation: Expected number of participants specified in abstract (see p. 2, line 38).

Reviewer 3 Comments: Methods: I recommendend to add the number of falls among the secondary outcomes "number of falls in the 3 months prior to intervention, number of falls at 3 months, 6 months, and 12 months").

Authors' explanation: Thank you for your genuine comments on this matter. To be clear the frequency of the data collection, will be immediately before the intervention (baseline) (T0), immediately post-intervention (T1), and at 12 weeks post-intervention (T2). Considering the literature and our study aim the number of falls is included in the baseline data collection. The falls history and frequency of falls of study participants in the last 12 months will be recorded at baseline. The details of our primary and secondary outcomes are to be measured at three different points in time (see p.10 lines 102 to 112).

Reviewer 3 Comments: Methods: non-inclusion criteria, replace "cognitive impairment" by "major cognitive impairment"

Authors' explanation: The term "cognitive impairment" is replaced by "major cognitive impairment" (see p. 16, line 149).

Reviewer 3 Comments: Methods: Student's t-test will be probably used to compare the level of frailty with categorical variables (sex, education, etc). Add Student's t-test.

Authors' explanation: Student's t-test will used to compare the level of frailty with categorical variables (see p. 24, line 274-275).

Reviewer 4 Comments: Line 111.6, it is unclear why the study was registered PROSPECTIVELY 3 months after data collection. Should it be RETROSPECTIVELY as registration of the study happened after the start of data collection?

Authors' explanation: Thank you for your observation on this matter. This has been addressed in the revised manuscript (see p. 15, line 121).

Reviewer 4 Comments: Line 113-133, If the data is assumed to be normally distributed, why paired-t test is not used for sample size calculation? Also, please clarify the end point of the primary outcome for sample size calculation, either from T0 to T1 or T0 to T2.

Authors' explanation: Even though we used the Wilcoxon signed rank test we considered normal parent distribution methods to determine the sample using G-Power. The endpoint for the primary outcome for sample size calculation is from T0 to T2.

Reviewer 4 Comments: The author should state clearly which outcome measure is used for sample size calculation as the assumed effect size of 0.5 means it is assumed that the effect size of the intervention on the primary outcome of the study is 0.5, which should also be supported by evidence.

Authors' explanation: The primary outcome measure, frailty, was used for sample size calculation.

We set the effect size at 0.5 as it is often used as a practical rule of thumb, especially when there is no prior knowledge or specific expectations about the effect size. It provides a balance between detecting meaningful effects and ensuring a feasible sample size. A moderate effect size of 0.5 is considered large enough to be practically significant in many fields (Althubaiti, 2023).

Reviewer 4 Comments: Line 137-144, it is unclear how the subjects will be recruited, either from the poster or CHW proactively to recruit subjects through the available list. More specifically, which sampling method will be used?

Authors' explanation: The reason for distributing a poster containing the aim of the study, eligibility criteria, and benefits of participating in the study was to make it readily available to anyone who need to take part in the study. However, we have made a revision so that it will be clearer how the subjects will be recruited. The study participants will be recruited using convenient sampling (see p. 16, lines 152 to 153, lines 155 to 156).

Reviewer 4 Comments: The section Recruitment should place after the section on Eligibility.

Authors' explanation: A revision has been made based on the comment (see p. 16 line 142 and 152).

Reviewer 4 Comments: Line 169, for the NLI program, the sessions can be distinct and interconnected (independent means they are unconnected)

Authors' explanation: A revision has been made based on the comment (see p. 17 line 172).

Reviewer 4 Comments: Line 226. Some descriptions of the outcome measures should be provided in the text, rather than provided in the hypothesis under Study design and hypothesis. Moreover, some of the outcomes were not touched such as recent appetite.

Authors' explanation: Thank you for your insights on this section.

In the study design and hypothesis section, we tried to amend the flow.

We believe that the outcome measurement descriptions are provided and explained at the end of the hypothesis and design section. Moreover, a brief description of each outcome measure, measurement tools and frequency of measurement has been indicated in Table 2. ‘Recent appetite’ has been included as one of the outcome measures in the revised manuscript (see p. 10, lines 109). The measurement tool description for this outcome has been described in Table 2, section VI.

Reviewer 4 Comments: Acceptability of the program should also be measured from the perspectives of the participants on top of the interventionist (i.e., CHWs)

Authors' explanation: Acceptability of the program from the perspective of the participants will be recorded. This has been stated in the revised manuscript (see p. 23 lines 263 to 264).

Reviewer 4 Comments: Line 272-285, Please group the points for two subsections of strengths and limitations of the study.

Authors' explanation: Two subsections have been made in the revised version (see p. 25 line 304 and line 311).

Attachments
Attachment
Submitted filename: Response to Reviewers_PLOS ONE_02.12.23.docx
Decision Letter - Azmeraw Ambachew Kebede, Editor

Measuring the Effects of a Nurse-led Intervention on Frailty Status of Older People Living in the Community in Ethiopia: A Protocol for a Quasi-experimental Study

PONE-D-23-00901R2

Dear Dr. Kasa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Azmeraw Ambachew Kebede, MSc

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Formally Accepted
Acceptance Letter - Azmeraw Ambachew Kebede, Editor

PONE-D-23-00901R2

PLOS ONE

Dear Dr. Kasa,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Mr. Azmeraw Ambachew Kebede

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .